Detalhe da pesquisa
1.
The FACIT-AI, a new tool for assessing symptoms associated with malignant ascites.
Gynecol Oncol
; 128(2): 187-90, 2013 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-23159815
2.
Patient Preferences for Multi-Cancer Early Detection (MCED) Screening Tests.
Patient
; 16(1): 43-56, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35844011
3.
Performance of a Cell-Free DNA-Based Multi-cancer Detection Test in Individuals Presenting With Symptoms Suspicious for Cancers.
JCO Precis Oncol
; 7: e2200679, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37467458
4.
Metastatic mucinous ovarian cancer and treatment decisions based on histology and molecular markers rather than the primary location.
J Natl Compr Canc Netw
; 10(9): 1076-80, 2012 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-22956806
5.
Evaluation of cell-free DNA approaches for multi-cancer early detection.
Cancer Cell
; 40(12): 1537-1549.e12, 2022 12 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36400018
6.
Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients.
Proc Natl Acad Sci U S A
; 105(8): 3005-10, 2008 Feb 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-18287062
7.
Prognostic Significance of Blood-Based Multi-cancer Detection in Plasma Cell-Free DNA.
Clin Cancer Res
; 27(15): 4221-4229, 2021 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34088722
8.
CD133 expression defines a tumor initiating cell population in primary human ovarian cancer.
Stem Cells
; 27(12): 2875-83, 2009 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-19816957
9.
Phase II trial of GM-CSF in women with asymptomatic recurrent müllerian tumors.
Gynecol Oncol
; 116(2): 168-72, 2010 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-19922985
10.
Risk stratification for desensitization of patients with carboplatin hypersensitivity: clinical presentation and management.
J Allergy Clin Immunol
; 123(6): 1262-7.e1, 2009 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-19501233
11.
Modulation of drug resistance in ovarian adenocarcinoma by enhancing intracellular ceramide using tamoxifen-loaded biodegradable polymeric nanoparticles.
Clin Cancer Res
; 14(10): 3193-203, 2008 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-18483388
12.
Modulation of intracellular ceramide using polymeric nanoparticles to overcome multidrug resistance in cancer.
Cancer Res
; 67(10): 4843-50, 2007 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-17510414
13.
Phase I clinical trial of STA-4783 in combination with paclitaxel in patients with refractory solid tumors.
Clin Cancer Res
; 13(2 Pt 1): 584-90, 2007 Jan 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-17255281
14.
Pooling of case specimens to create standard serum sets for screening cancer biomarkers.
Cancer Epidemiol Biomarkers Prev
; 16(2): 334-41, 2007 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-17301268
15.
Phase II study of intraperitoneal recombinant interleukin-12 (rhIL-12) in patients with peritoneal carcinomatosis (residual disease < 1 cm) associated with ovarian cancer or primary peritoneal carcinoma.
J Transl Med
; 5: 66, 2007 Dec 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-18076766
16.
SD-1029 inhibits signal transducer and activator of transcription 3 nuclear translocation.
Clin Cancer Res
; 12(22): 6844-52, 2006 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-17121906
17.
Signal transducers and activators of transcription 3 pathway activation in drug-resistant ovarian cancer.
Clin Cancer Res
; 12(17): 5055-63, 2006 Sep 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-16951221
18.
Chemosensitization to cisplatin by inhibitors of the Fanconi anemia/BRCA pathway.
Mol Cancer Ther
; 5(4): 952-61, 2006 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-16648566
19.
Multicenter, randomized phase II trial of oral CI-1033 for previously treated advanced ovarian cancer.
J Clin Oncol
; 23(24): 5597-604, 2005 Aug 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-16110019
20.
GBP1 overexpression is associated with a paclitaxel resistance phenotype.
Cancer Chemother Pharmacol
; 57(1): 25-33, 2006 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-16028104